Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination
Authors
Keywords
-
Journal
Human Vaccines & Immunotherapeutics
Volume 10, Issue 5, Pages 1155-1165
Publisher
Informa UK Limited
Online
2014-02-28
DOI
10.4161/hv.28022
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme
- (2014) Maria-Genalin Angelo et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial
- (2013) M. Safaeian et al. Cancer Prevention Research
- Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women
- (2013) Simon R. M. Dobson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Immunogenicity of Quadrivalent HPV Vaccine Among Girls 11 to 13 Years of Age Vaccinated Using Alternative Dosing Schedules: Results 29 to 32 Months After Third Dose
- (2013) D. S. LaMontagne et al. JOURNAL OF INFECTIOUS DISEASES
- Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study
- (2013) Lynette Denny et al. VACCINE
- Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer
- (2012) Peng Guan et al. INTERNATIONAL JOURNAL OF CANCER
- Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10–25-Year-Old HIV-Seronegative African Girls and Young Women
- (2012) Papa Salif Sow et al. JOURNAL OF INFECTIOUS DISEASES
- Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination
- (2012) Kinga K. Smolen et al. VACCINE
- Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women
- (2012) A.-B. Moscicki et al. VACCINE
- Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine
- (2012) Cecilia M. Roteli-Martins et al. Human Vaccines & Immunotherapeutics
- Development of an AS04-Adjuvanted HPV Vaccine with the Adjuvant System Approach
- (2011) Nathalie Garçon et al. BIODRUGS
- Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine
- (2011) Francis J. Dessy et al. Human vaccines & immunotherapeutics
- Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine
- (2011) Tino F. Schwarz et al. Human vaccines & immunotherapeutics
- Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years
- (2011) Tino F. Schwarz et al. Human vaccines & immunotherapeutics
- Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years
- (2011) Mark H. Einstein et al. Human vaccines & immunotherapeutics
- Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule
- (2011) Barbara Romanowski et al. Human vaccines & immunotherapeutics
- Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine
- (2011) Mark H. Einstein et al. Human vaccines & immunotherapeutics
- Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine
- (2011) Aimée R. Kreimer et al. JNCI-Journal of the National Cancer Institute
- Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
- (2011) Matti Lehtinen et al. LANCET ONCOLOGY
- Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
- (2011) Cosette M Wheeler et al. LANCET ONCOLOGY
- Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years
- (2010) Mark H. Einstein et al. Human vaccines & immunotherapeutics
- Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens inCervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine
- (2010) Michel Deschuyteneer et al. Human vaccines & immunotherapeutics
- Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007–2008
- (2010) La'Shan D. Taylor et al. PREVENTIVE MEDICINE
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
- (2009) J Paavonen et al. LANCET
- Prophylactic HPV vaccines: New interventions for cancer control
- (2008) Eliav Barr et al. VACCINE
- Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines
- (2008) Thomas Verstraeten et al. VACCINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now